Pharmacogenetics and irinotecan therapy

American Journal of Health-System Pharmacy

Volumn 63, Issue 22, 2006, Pages 2211-2217

  Hahn, Kristine K ^a   Wolff, James J ^b   Kolesar, Jill M ^a,b,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c U of WI School of Pharmacy   (United States)

Author keywords

Antineoplastic agents; Colorectal neoplasms; Dosage; Genetics; Irinotecan; Labeling; Metabolism; Neoplasm metastasis; Pharmacogenetics; Pharmacokinetics; Polymorphism; Tests; Toxicity

Indexed keywords

7 ETHYL 10 (4 AMINO 1 PIPERIDINO)CARBONYLOXYCAMPTHOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; BETA GLUCURONIDASE; BILIRUBIN; CAPECITABINE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; COLONY STIMULATING FACTOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; RALTITREXED; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; COLORECTAL CANCER; DEATH; DEHYDRATION; DIARRHEA; DRUG BILE LEVEL; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSFORMATION; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEREDITY; HOMOZYGOTE; HOSPITALIZATION; HUMAN; INDIVIDUALIZATION; INFECTION; INTERPATIENT VARIABILITY; LEUKOPENIA; METASTASIS; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TATA BOX; UGT1A1 GENE;

EID: 33845228082     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060155     Document Type: Review

References (40)

1. American Cancer Society. Overview: colon and rectal cancer. www.cancer. org/docroot/CRI/CRI_2_1x.asp?dt=10 (accessed 2006 Mar 13).
2. Food and Drug Administration. Camptosar prescribing information. www.fda.gov/cder/foi/label/2005/ 020571s024,027,028lbl.pdf (accessed 2006 Aug 9).
3. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol. 2002; 20:7-8. Editorial.
4. Mathijssen RH, Verweij J, de Jonge MJ et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol. 2002; 20:81-7.
5. Food and Drug Administration. 2002 Safety alert: Camptosar (irinotecan hydrochloride injection). www.fda.gov/ medwatch/SAFETY/2002/camptosar.htm (accessed 2006 Feb 25).
6. Gupta E, Lestingi TM, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994; 54:3723-5.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer, v.2.2006. www.nccn.org (accessed 2006 Jun 12).
8. Gagne JF, Montminy V, Belanger P et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10- hydroxycamptothecin (SN-38). Mol Pharmacol. 2002; 62:608-17.
9. Ando Y, Saka H, Ando M et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000; 60:6921-6.
10. Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2:43-7.
11. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004; 22:1382-8.
12. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol. 2002; 62:446-50.
13. Fuchs CS, Moore MR, Harker G et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003; 21:807-14.
14. Innocenti F, Ratain MJ. Irinotecan treatments in cancer patients with UGT1A1 polymorphisms. Oncology. 2003; 17 (suppl 5):52-5.
15. Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998; 101:847-54.
16. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003; 13:517-23.
17. McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol. 2004; 22:1356-9. Editorial.
18. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci. 1998; 95:8170-4.
19. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995; 333:1171-5.
20. Ando Y, Saka H, Asai G et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol. 1998; 9:845-7.
21. Iyer L, Hall D, Das S et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999; 65:576-82.
22. Mathijssen RH, Marsh S, Karlsson MO et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003; 9:3246-53.
23. Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs. 2003; 21:435-43.
24. Rouits E, Boisdron-Celle M, Dumont A et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004; 10:5151-9.
25. Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004; 91:678-82.
26. Paoluzzi L, Singh AS, Price DK et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004; 44:854-60.
27. Carlini LE, Meropol NJ, Bever J et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005; 11:1226-36.
28. Soepenberg O, Dumez H, Venweij J et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res. 2005; 11:1504-11.
29. Massacesi C, Terrazzino S, Marcucci F et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-hased chemotherapy. Cancer. 2006; 106:1007-16.
30. Innocenti F, Grimsley C, Das S et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002; 12:725-33.
31. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001; 19:1501-18.
32. Meyerhardt JA, Kwok A, Ratain MJ et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22:1439-46.
33. Invader UGT1A1 molecular assay package insert. Madison, WI: Third Wave Technologies; 2005 Aug.
34. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy irinotecan (Camptosar). Med Lett Drugs Ther. 2006; 48:39-40.
35. Steiner M, Seule M, Steiner B et al. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol. 2005; 58:553-5.
36. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics. 2004; 5:835-43.
37. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006; 20:163-75.
38. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23-30.
39. Varadhachary GR, Hoff PM. Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. Semin Oncol. 2005; 32(6, suppl 9):40-2.
40. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist. 2005; 10:701-9.